Aussie Antisense Therapeutics up on trial nod for muscular dystrophy drug

Percheron Therapeutics

26/04/2023 04:08

** Shares of Antisense Therapeutics Ltd  ANP.AX  rise as
much as 8% to A$0.081, on track for best day since Feb 17
    ** Biotechnology company says it received approval  to
conduct mid-stage  trials of ATL1102 in non-ambulant boys with
Duchenne muscular dystrophy in Bulgaria 
    ** Says requisite contracts have also been executed with the
Bulgarian trial site to immediately set it up
    ** Stock down ~23% this year, as of last close


 (Reporting by Poonam Behura in Bengaluru)
 ((Poonam.Behura@thomsonreuters.com;))